The financials
Arcutis Biotherapeutics, Inc. by the numbers
Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $130M in Q2 2026 (quarter ended Jun 30, 2026), up 59% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $15M (12% of revenue). For the full year FY2025, revenue was $376M (+91% year on year) and net income −$16M. Its largest product in Q2 2026 was ZORYVE Foam at $67M, 52% of the disclosed total, well ahead of ZORYVE Cream0.3 at 27%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $130M | $82M | +59% |
| Gross profit | $119M | $74M | +61% |
| Operating income | $16M | −$15M | to a profit |
| Net income | $15M | −$16M | to a profit |
| Diluted EPS | $0.11 | −$0.13 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| ZORYVE Foam | $67M | 52% |
| ZORYVE Cream0.3 | $35M | 27% |
| ZORYVE Cream0.15 | $24M | 19% |
| ZORYVE Cream0.05 | $2.9M | 2.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $129.9M (+23%)
ZORYVE Foam grew +72% year on yearZORYVE Cream0.3 +28% year on year
Segment Latestquarter on quarteryear on year
- ZORYVE Foam$67.4M$67.4MQoQ +36%year on year +72%+36%+72%
- ZORYVE Cream0.3$35.3M$35.3MQoQ +8.1%year on year +28%+8.1%+28%
- ZORYVE Cream0.15$24.2M$24.2MQoQ +11%year on year +66%+11%+66%
- ZORYVE Cream0.05$2.9M$2.9MQoQ +115%year on year -+115%-